CVRx Q4 2023 Earnings Report $16.25 +0.79 (+5.11%) As of 02/4/2025 04:00 PM Eastern Earnings HistoryForecast CVRx EPS ResultsActual EPS-$0.44Consensus EPS -$0.55Beat/MissBeat by +$0.11One Year Ago EPSN/ACVRx Revenue ResultsActual Revenue$11.31 millionExpected Revenue$10.90 millionBeat/MissBeat by +$410.00 thousandYoY Revenue GrowthN/ACVRx Announcement DetailsQuarterQ4 2023Date1/25/2024TimeN/AConference Call ResourcesPress ReleaseCVRX Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by CVRx Earnings HeadlinesCVRx sees FY25 revenue $ $63M -$65M, consensus $64.16MFebruary 5 at 3:07 AM | markets.businessinsider.comCVRx reports Q4 EPS (43c), consensus (38c)February 5 at 3:07 AM | markets.businessinsider.comPlease take this warning seriously...I’m here to issue a stark warning to you about an unexpected $2 trillion shock that could impact every trader in the country – in the next 30 days. In fact, I believe it could begin as soon as March 13th… Meaning you don’t have much time to prepare.February 5, 2025 | Timothy Sykes (Ad)CVRx targets $63M-$65M revenue in 2025 with strengthened sales strategyFebruary 5 at 3:07 AM | msn.comCVRx, Inc. (CVRX) Q4 2024 Earnings Conference Call TranscriptFebruary 5 at 12:03 AM | seekingalpha.comCVRx Reports Fourth Quarter and Full Year 2024 Financial and Operating ResultsFebruary 4 at 4:05 PM | globenewswire.comSee More CVRx Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CVRx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CVRx and other key companies, straight to your email. Email Address About CVRxCVRx (NASDAQ:CVRX), a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.View CVRx ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Palantir Stock Surges After Blockbuster Earnings: What's Next?Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip? Upcoming Earnings AstraZeneca (2/6/2025)Fortinet (2/6/2025)Amazon.com (2/6/2025)Linde (2/6/2025)Sumitomo Mitsui Financial Group (2/6/2025)ING Groep (2/6/2025)ConocoPhillips (2/6/2025)KKR & Co. Inc. (2/6/2025)Intercontinental Exchange (2/6/2025)Thomson Reuters (2/6/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
